Climb Bio to be Added to the Nasdaq Biotechnology Index
December 19, 2024 07:00 ET
|
Climb Bio, Inc.
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)...
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024 16:05 ET
|
Climb Bio, Inc.
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management...
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
November 11, 2024 07:00 ET
|
Climb Bio, Inc.
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr....
Climb Bio to Present at Upcoming Investor Conferences
October 31, 2024 07:00 ET
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences...
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
October 15, 2024 07:00 ET
|
Climb Bio, Inc.
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
October 11, 2024 12:30 ET
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place...
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
October 04, 2024 07:00 ET
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by...
Climb Bio to Host Virtual Investor Event on October 15, 2024
October 03, 2024 10:00 ET
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb...
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
October 02, 2024 09:00 ET
|
Eliem Therapeutics, Inc.
Name change to "Climb Bio" marks the Company’s transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM"...
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
September 11, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024...